Enanta Pharmaceuticals
ENTA
172 hedge funds and large institutions have $862M invested in Enanta Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 76 increasing their positions, 55 reducing their positions, and 24 closing their positions.
38% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 55
2.52% more ownership
Funds ownership: 91.34% → 93.87% (+2.5%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less funds holding
Funds holding: 180 → 172 (-8)
6% less capital invested
Capital invested by funds: $917M → $862M (-$54.8M)
33% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 24
100% less call options, than puts
Call options by funds: $4K | Put options by funds: $2.15M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$20.3M |
| 2 |
AC
Armistice Capital
New York
|
+$9.69M |
| 3 |
BlackRock
New York
|
+$8.97M |
| 4 |
Millennium Management
New York
|
+$4.31M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$4.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$14.9M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$6.32M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$4.69M |
| 4 |
State Street
Boston,
Massachusetts
|
-$4.63M |
| 5 |
WG
Winton Group
London,
United Kingdom
|
-$3.29M |
ENTA Hedge Fund Activity: Q3 2020 in Review
172 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q3 2020, worth a combined $862M — down 6% from $917M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of ENTA and 16 opened new positions — a net loss of 8 holders — while 55 trimmed existing stakes and 76 added.
The largest buyer was Invesco, adding an estimated $20.3M. The largest seller was T. Rowe Price Associates, cutting an estimated $14.9M.
- 172 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q3 2020, down from 180 in Q2 2020.
- Funds reported $862M of Enanta Pharmaceuticals stock for Q3 2020, down 6% quarter-over-quarter.
- 16 funds opened new Enanta Pharmaceuticals positions in Q3 2020 and 24 closed out, a net change of -8 holders.
- The largest Enanta Pharmaceuticals buyer in Q3 2020 was Invesco, an estimated $20.3M added.
- The largest Enanta Pharmaceuticals seller in Q3 2020 was T. Rowe Price Associates, an estimated $14.9M sold.
Based on aggregated 13F filings for Q3 2020.